|
NICE says pancreatic cancer treatment considered not cost effective for routine NHS use
NICE approves three quarters of CDF group 1 drugs for routine use
NICE: Price discount helps give green light for breast cancer drug pertuzumab
NICE: NICE welcomes landmark fall in antibiotic prescriptions
NHS England: New measures to support whistleblowers in primary care
FCA publishes rules for the sale of the Lifetime ISA
ESMA finalises Guidelines on the validation and review of CRAs’ methodologies
|
.png)
